CD79 (AA 202-216) antibody

Catalog No. ABIN3024095

This Mouse Monoclonal antibody specifically detects CD79 in FACS, IF and IHC (p). It exhibits reactivity toward Human.

Quick Overview for CD79 (AA 202-216) antibody (ABIN3024095)

Target: CD79

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: Un-conjugated

Application: Flow Cytometry (FACS), Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: SPM549

Product Details

Binding Specificity: AA 202-216

Purification: Protein G affinity chromatography

Immunogen: Amino acids 202-216 (GTYQDVGSLNIADVQ-human) from the alpha chain were used as the immunogen for this CD79 antibody.

Isotype: IgG1 kappa

Application Details

Application Notes: The optimal dilution of the CD79 antibody for each application should be determined by the researcher.

1. Staining of formalin-fixed tissues requires boiling tissue sections in 10  mM citrate buffer,  pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.\. Flow Cytometry: 0.5-1 μg/million cells in 0.1ml,Immunofluorescence: 0.5-1 μg/mL,Immunohistochemistry (FFPE): 0.25-0.5 μg/mL for 30 min at RT (1),Prediluted format: incubate for 30 min at RT (2)

Restrictions: For Research Use only

Handling

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Preservative: Azide free

Storage: 4 °C,-20 °C

Storage Comment: Store the CD79 antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).

Target Details

Target: CD79

Background: A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in some myelomas. It is not present in myeloid or T cell lines. Anti-CD79a is generally used to complement anti-CD20 especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This antibody will stain many of the same lymphomas as anti-CD20, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is anti-CD20. Anti-CD79a also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well.